AimedBio Q1 2026: Tech Transfer Revenue Surges, Operating Loss Persists
Consolidated Q1 2026 revenue of KRW 8,498 million (sharp increase vs prior quarter, tech transfer revenue 98.6%), operating loss of KRW 3,956 million, net loss of KRW 2,011 million.
Cash and cash equivalents fell sharply to KRW 11,837 million from end-2025; total financial assets including short-term products stood at KRW 170,452 million.
Key pipeline: AMB302 (FGFR3 ADC for bladder cancer) in US Phase 1; ODS025 (undisclosed target) licensed to Boehringer Ingelheim; AMB303 (ROR1 ADC) co-developed with SK Plasma.
R&D expenses of KRW 10,913 million, approximately 4x higher than Q1 2025, representing 147% of revenue.
Debt ratio of 4.1% indicates sound financial structure; no contingent liabilities or litigation.
Total equity of KRW 191.9 billion, significantly increased due to KOSDAQ listing in December 2025.